A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 2045-7634|4|5|643-650

ISSN： 2045-7634

Source： Cancer Medicine, Vol.4, Iss.5, 2015-05, pp. : 643-650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

By Bedikian Agop   Papadopoulos Nicholas   Kim Kevin   Hwu Wen-Jen   Homsi Jade   Glass Michelle   Cain Suzanne   Rudewicz Patrick   Vernillet Laurent   Hwu Patrick  

Cancer Investigation, Vol. 27, Iss. 7, 2009-08 ,pp. : 756-763

Informa Healthcare

Access to resources Recommend Favorite

Induction therapy with cetuximab plus docetaxel, cisplatin, and 5‐fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO‐07 study

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 721-731

John Wiley & Sons Inc

Access to resources Recommend Favorite

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

By Livingston Robert   Barlow William   Kash Joseph   Albain Kathy   Gralow Julie   Lew Danika   Flaherty Lawrence   Royce Melanie   Hortobagyi Gabriel  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 123-131

Springer Publishing Company

Access to resources Recommend Favorite

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

By Nishimura Kazuo  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 306-313

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

By Somlo G.   Martel C.   Lau S.   Frankel P.   Ruel C.   Gu L.   Hurria A.   Chung C.   Luu T.   Morgan R.   Leong L.   Koczywas M.   McNamara M.   Russell C.   Kane S.  

Breast Cancer Research and Treatment, Vol. 131, Iss. 3, 2012-02 ,pp. : 899-906

Springer Publishing Company

Access to resources Recommend Favorite